### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average burden							
hours per response	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	es)																
Name and Address of Reporting Person * Naydenov Jordan G					2. Issuer Name and Ticker or Trading Symbol CytoDyn Inc. [CYDY]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  _X_Director					
(Last) (First) (Middle) 1111 MAIN STREET, SUITE 660				_	3. Date of Earliest Transaction (Month/Day/Year) 06/01/2017									ve title below)		r (specify below)		
(Street)			4	4. If Amendment, Date Original Filed(Month/Day/Year)								6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person						
VANCOUVER, WA 98660 (City) (State) (Zip)							Tab	le I -	Non-Deriv	vative S	Securities	Acquired	, Dispose	d of, or Ben	eficially Own	ed		
1.Title of Security (Instr. 3)  2. Transaction Date (Month/Day/Year			ay/Year)	2A. Deemed Execution Date any (Month/Day/Ye		(Instr. 8		8) (	4. Securities Acqu (A) or Disposed of (Instr. 3, 4 and 5)  (A) or Amount (D)		of (D) Ow Tra		wing Report )			Nature Indirect eneficial wnership nstr. 4)		
Reminder:	Report on a	separate line for ea		ıble II - D	erivativ	e Se	curities	Acqu	Persoi contai	ns who ned in display	this for ys a curr of, or Bene	m are not ently vali eficially O	t require d OMB c	n of inform d to respon ontrol nun	nd unless th		74 (9-02)	
1. Title of Derivative Security (Instr. 3)	Conversion	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if	ned n Date, if	4. Transaction Code		5. Number		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title ar Amount o Underlyin Securities (Instr. 3 a	of ng		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (II) (Instr. 4)	Beneficial Ownership (Instr. 4)		
				Code	V	(A)	(D)	Date Exercisab		oiration e	Title	Amount or Number of Shares						
Stock Options (right to buy)	\$ 0.57	06/01/2017			A		75,000	)	(1)	06/	01/2027	Common Stock	n 75,000	\$ 0	75,000	D		
Repor	ting O	wners																
Reporting Owner Name / Address		Relation 10% Own		nar	Other													
Navdenov Jordan G		Director	10/0 OWI	OIII	CCI	Julei												

## **Signatures**

/s/ Michael D. Mulholland, as attorney-in-fact	06/05/2017
**Signature of Reporting Person	Date

X

# **Explanation of Responses:**

1111 MAIN STREET, SUITE 660

VANCOUVER, WA 98660

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Subject to stockholder approval, at the next annual meeting, of the increase in the number of shares of common stock authorized for issuance under the CytoDyn Inc. 2012 Equity Incentive Plan, as amended, the options will vest in four equal quarterly installments commencing on September 1, 2017.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.